Team of investigators with Virginia Commonwealth University, the Beijing Institute of Pharmacology and Toxicology in China, and the University of Aberdeen in Scotland assessed the influence of delta-8 THCV in seven different rodent models relevant to nicotine dependence.
They reported that the compound "significantly attenuated intravenous nicotine self-administration, and both cue-induced and nicotine-induced relapse to nicotine-seeking behavior in rats [and] also significantly attenuated nicotine-induced conditioned place preference and nicotine withdrawal in mice."
Authors concluded, "Δ8 -THCV may have therapeutic potential for the treatment of nicotine dependence. We also suggest that tetrahydrocannabivarins should be tested for possible anti-addiction efficacy in a broader range of preclinical animal models, against other addictive drugs, and eventually in humans."
The results of a 2013 clinical trial published in the journal Addictive Behaviors identified an association between the administration of the cannabinoid CBD and a reduction in the consumption of tobacco cigarettes.
For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, "Δ8 – Tetrahydrocannabivarin has potent anti-nicotine effects in multiple models of nicotine dependence," appears in the British Journal of Pharmacology.